OBJECTIVES

The following study investigated the impact of poor prognostic factors in HR+/HER2- aBC patients in Canada on treatment patterns and outcomes.

METHODS :

Real world data were drawn from the aBC Disease-specific Programme^TM - a point in time survey administered to oncologists who completed patient record forms for the next 10 HR+/HER2- aBC patients with whom they consulted in Q3 2018 in Canada. Poor prognostic factors assessed within this study included liver metastases presence, high tumour grade, ECOG score of 1-3, progesterone receptor-negative (PgR-), and a treatment free interval between adjuvant and 1^st line advanced treatment (1L) of <36 months.

RESULTS

Data analysis was conducted on 144 patients diagnosed with HR+/HER2- aBC. Patients had a mean age of 64.5 (SD=12.81) and 47% were diagnosed de novo advanced. 60% of patients were 1L and 29% were on 2L at time of study. Endocrine monotherapy (EM) (54%) was the most common treatment received at 1L, followed by endocrine + targeted therapy (ET) (33%) and chemotherapy (12%). Physicians reported that 19% of patients had disease progression at time of study.

24% patients had 0 prognostic factors, 33%, 26%, 14% and 3% patients had 1, 2, 3 and 4 poor prognostic factors respectively. As the number of poor prognostic factors increased (0-4), patient age decreased (64.1, 68.0, 64.0, 61.0, 52.8), use of chemotherapy at 1L increased (6%, 2%, 21%, 20%, 40%), duration (days) of 1L decreased (430.3, 287.0, 227.4, 169.2, 43.0) and proportion of patients with a progressing disease increased (6%, 11%, 26%, 35%, 60%).

CONCLUSIONS :

Patients with more poor prognostic factors were more likely to receive chemotherapy and have worse outcomes, illustrating an unmet medical need within this population of patients.